|
|
|
Insider
Information: |
Clague Laura |
Relationship: |
Director |
City: |
San Diego |
State: |
CA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
3 |
|
Direct
Shares |
424,757 |
|
Indirect Shares
|
2,000 |
|
|
Direct
Value |
$1,037,526 |
|
|
Indirect Value
|
$3,800 |
|
|
Total
Shares |
426,757 |
|
|
Total
Value |
$1,041,326 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
3
|
Stock
price went up :
|
0
|
1
|
Stock
price went down : |
0
|
2
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
-32.4%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Genasys Inc |
GNSS |
Director |
2022-04-27 |
284,311 |
2022-04-27 |
2,000 |
Premium* |
|
Travere Therapeutics, Inc |
TVTX |
Chief Financial Officer |
2022-05-11 |
35,655 |
2018-02-08 |
0 |
Premium* |
|
Fluidigm Corp |
FLDM |
Director |
2023-06-14 |
104,791 |
2018-10-30 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
65 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 3
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2020-05-12 |
4 |
AS |
$16.98 |
$30,401 |
D/D |
(1,777) |
19,473 |
0 |
% |
|
FLDM |
Fluidigm Corp |
Director |
|
2020-06-23 |
4 |
A |
$0.00 |
$0 |
D/D |
13,369 |
27,356 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2020-09-18 |
4 |
A |
$0.00 |
$0 |
D/D |
3,000 |
22,473 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2020-09-22 |
4 |
AS |
$18.59 |
$27,885 |
D/D |
(1,500) |
20,973 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2020-09-23 |
4 |
AS |
$18.48 |
$27,720 |
D/D |
(1,500) |
19,473 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2020-11-11 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
34,473 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2020-11-13 |
4 |
AS |
$23.61 |
$177,071 |
D/D |
(7,500) |
26,973 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2020-11-16 |
4 |
AS |
$23.98 |
$179,813 |
D/D |
(7,500) |
19,473 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2020-11-23 |
4 |
A |
$0.00 |
$0 |
D/D |
7,500 |
26,973 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2020-11-24 |
4 |
AS |
$23.86 |
$89,475 |
D/D |
(3,750) |
23,223 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2020-11-25 |
4 |
AS |
$22.72 |
$85,200 |
D/D |
(3,750) |
19,473 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2021-01-21 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
34,473 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2021-01-31 |
4 |
A |
$0.00 |
$0 |
D/D |
5,000 |
39,473 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2021-02-02 |
4 |
AS |
$30.75 |
$111,469 |
D/D |
(3,625) |
35,848 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2021-02-03 |
4 |
AS |
$28.91 |
$104,799 |
D/D |
(3,625) |
32,223 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2021-02-03 |
4 |
A |
$0.00 |
$0 |
D/D |
4,500 |
36,723 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2021-02-05 |
4 |
AS |
$31.41 |
$70,673 |
D/D |
(2,250) |
34,473 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2021-02-08 |
4 |
AS |
$31.58 |
$71,055 |
D/D |
(2,250) |
32,223 |
0 |
% |
|
FLDM |
Fluidigm Corp |
Director |
|
2021-02-20 |
4 |
A |
$0.00 |
$0 |
D/D |
9,803 |
37,159 |
0 |
- |
|
GNSS |
Genasys Inc |
Director |
|
2021-03-10 |
4 |
OE |
$2.02 |
$40,400 |
D/D |
20,000 |
175,600 |
0 |
- |
|
GNSS |
Genasys Inc |
Director |
|
2021-03-10 |
4 |
S |
$7.42 |
$40,465 |
D/D |
(5,456) |
170,144 |
0 |
% |
|
GNSS |
Genasys Inc |
Director |
|
2021-03-16 |
4 |
A |
$0.00 |
$0 |
D/D |
27,883 |
168,027 |
0 |
- |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2021-05-11 |
4 |
AS |
$19.14 |
$38,280 |
D/D |
(2,000) |
30,223 |
0 |
% |
|
TVTX |
Travere Therapeutics, Inc |
Chief Financial Officer |
|
2021-05-12 |
4 |
AS |
$19.46 |
$38,920 |
D/D |
(2,000) |
28,223 |
0 |
% |
|
FLDM |
Fluidigm Corp |
Director |
|
2021-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
10,342 |
47,501 |
0 |
- |
|
65 Records found
|
|
Page 2 of 3 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|